Cancer Treatment Reviews
Volume 31, Issue 3 , Pages 236-241 , May 2005

Adding irinotecan to first-line gemcitabine improves tumour response in advanced pancreatic cancer: Abstracted from: Rocha Lima CM, Green MR, Rotche R et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumour response rate. J Clin Oncol 2004;22:3776–83.

  • Desmond Yip, MBBS, FRACP

      Affiliations

    • Medical Oncology Unit, The Canberra Hospital and Australian National University Medical School, Canberra, Australia
    • Corresponding Author InformationCorresponding author. Tel.: +61 262 442 220; fax: +61 262 444 266
    • ,
  • David Goldstein, MBBS, FRACP

      Affiliations

    • Prince of Wales Hospital and University of New South Wales, Sydney, Australia

References 

  1. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial [see comments]. J Clin Oncol. 1997;15:2403–2413
  2. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22:3776–3783
  3. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002;20:3270–3275
  4. Wang X, Ni Q, Jin M, et al. Gemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancer. Zhonghua Zhong Liu Za Zhi. 2002;24:404–407
  5. Heinemann V, Quietzsch D, Gieseler F, et al. A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma. Proc Am Soc Clin Oncol. 2003;21:(Abstract 1003)
  6. Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell’Italia Meridionale. Cancer. 2002;94:902–910
  7. Li C, Chao Y. A prospective randomized trial of gemcitabine alone or gemcitabine+cisplatin in the treatment of metastatic pancreatic cancer. Proc Am Soc Clin Oncol Gastroint Canc Symp. 2004;1:(Abstract 140)
  8. Louvet C, Labianca R, Hammel P, et al. GemOx (gemcitabine+oxaliplatin) versus Gem (gemcitabine) in non-resectable pancreatic adenocarcinoma: Final results of the GERCOR/GISCAD Intergroup Phase III. Proc Am Soc Clin Oncol. 2004;23:(Abstract 4008)
  9. O Reilly E, Abou-Alfa G, Letourneau R, Harker W, et al. A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs. gemcitabine alone in advanced pancreatic cancer (APC). Proc Am Soc Clin Oncol. 2004;23:(Abstract 4006)
  10. Richards D, Kindler H, Oettle H, Ramanathan R, et al. A randomized phase III study comparing gemcitabine+pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer. Proc Am Soc Clin Oncol. 2004;23:(Abstract 4007)
  11. Reni M, Cordio S, Passardi A, Panucci MG, et al. Final results of a phase III trial of gemcitibine (G) versus PEFG regimen in stage IVA or metastatic pancreatic adecnocarcinoma (PA). Proc Am Soc Clin Oncol. 2004;23:(Abstract 4010)
  12. Ohkawa S. Randomized controlled trial of gemcitabine in combination with UFT versus gemcitabine alone in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol. 2004;22:(Abstract 4131)
  13. Buyse M, Thirion P, Carlson RW, et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-analysis Group in Cancer. Lancet. 2000;356:373–378
  14. Pierga JY, Robain M, Jouve M, et al. Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients. Ann Oncol. 2001;12:231–237
  15. Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer. 2002;87:161–167
  16. Van Cutsem E, Van De Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004;22:1430–1438
  17. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib improves survival when added to gemcitabine in patients wtih advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clincial Trials Group. Proc Am Soc Clin Oncol Gastroint Canc Symp. 2005;2:(Abstract 77)

☆ Sources of funding: Supported by a grant from Pfizer Corp. New York, NY, USA.

☆☆ For correspondence: Caio Max Sao Pedro Rocha Lima, MD, University of Miami and Sylvester Cance Center, 1475 NW 12th Avenue, Suite 3310, Miami, FL 33162, USA. E-mail: croche@med.miami.edu.

☆☆☆ Abstract provided by Bazian Ltd., London.

PII: S0305-7372(05)00053-8

doi: 10.1016/j.ctrv.2005.03.003

Cancer Treatment Reviews
Volume 31, Issue 3 , Pages 236-241 , May 2005

Article Tools